Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients

Clinical Neuropharmacology

Volumn 20, Issue 5, 1997, Pages 442-446

  Spivak, Baruch ^a,d   Mester, Roberto ^a,d   Wittenberg, Nathan ^b   Maman, Ziona ^a   Weizman, Abraham ^c,d  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aggression; Clozapine; Impulsiveness; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGGRESSION; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; IMPULSIVENESS; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SUICIDE;

EID: 0030820413     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199710000-00009     Document Type: Article

References (16)

1. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986;143:35-9.
2. Plutchik R, Van Praag HM. A self-report measure of violence risk. Part II. Compr Psychiatry 1990;31:450-6.
3. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry 1989;(suppl)15:52-62.
4. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Ant J Psychiatry 1995;152:183-90.
5. First MB, Spitzer RL, Gibbon M, Williams JSW. Structurnl intraview for axis I DSM-IV disorders, patient version (SCID-P), Hebrew version. Tel Aviv: Jakobsohn, 1994.
6. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
7. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
8. Plutchik R, van Praag HM. The measurement of suicidality, aggressivity and impulsivity. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:23-4.
9. Ratly JJ, Leveroni C, Kilmer D, Gutheil C, Swartz B. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 1993;54:219-23.
10. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implication for therapeutic and adverse effects. J Clin Psychiatry 1994;(suppl B)55:78-81.
11. Cohen SA, Underwood MT. The use of clozapine in a mentaly retarded and aggressive population. J Clin Psychiatry 1994;55:440-4.
12. Michals ML, Crismon ML, Roberts S, Childs A. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 1993;13:198-203.
13. Wilmot CA, Szczapanik AM. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 1989;487:288-98.
14. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41.
15. Stanly M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983;i:214-6.
16. Mallya AR, Roos PD, Roebuck-Colgan K. Restraint, seclusion, and clozapine. J Clin Psychiatry 1992;53:395-7.